Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) obtained approval to export tirzepatide as an active pharmaceutical ingredient (API) to the European Union, according to a Thursday filing with the Shanghai Stock Exchange.
Sinopep-Allsino's factory in Lianyungang passed the EU's good manufacturing practice compliance for export, the filing said.
Tirzepatide is indicated for type 2 diabetes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。